Abstract
Methylation of the WIF-1 gene can lead to the loss of WIF-1 expression which has been observed in numerous types of cancer including NSCLC. However, the association and clinicopathological significance between WIF-1 promoter hypermethylation and NSCLC remains unclear. In the present study, we performed a meta-analysis to evaluate the clinicopathological significance of WIF-1 hypermethylation in NSCLC. A systematic literature search was carried out using Pubmed, EMBASE, Web of Science and CNKI. The Cochrane software Review manager 5.2 was used. The frequency of WIF-1 hypermethylation was significantly increased in NSCLC compared with normal lung tissue; the pooled OR was 8.67 with 95% CI 1.64-45.88, p = 0.01. The rate of WIF-1 hypermethylation was higher in SCC than in AC, OR was 1.74 with 95% CI 0.97-3.11, p = 0.06. In addition, WIF-1 loss was correlated with low 5-year survival rate. In summary, WIF-1 hypermethylation is a potential biomarker for diagnosis of NSCLC. WIF-1 hypermethylation is predominant in squamous cell carcinoma (SCC), suggesting that WIF-1 methylation contributes to the development of NSCLC, especially SCC.
Highlights
Lung cancer has been the leading cause of cancerrelated mortality worldwide. [1] Lung cancer can be classified two major histological groups, small cell cancer and non-small cell lung cancer (NSCLC)
Wnt inhibitory factor-1 (WIF-1) hypermethylation is predominant in squamous cell carcinoma (SCC), suggesting that WIF-1 methylation contributes to the development of NSCLC, especially SCC
Methylation of the WIF-1 gene can lead to the loss of WIF-1 expression which has been observed in numerous types of cancer including NSCLC. [16,17,18,19,20] the association and clinicopathological significance between WIF-1 promoter hypermethylation and NSCLC remains unclear
Summary
Lung cancer has been the leading cause of cancerrelated mortality worldwide. [1] Lung cancer can be classified two major histological groups, small cell cancer and non-small cell lung cancer (NSCLC). WIF-1 has been identified as an important Wnt antagonist which inhibits Wnt/βcatenin signaling by directly binding to Wnt proteins. Methylation of the WIF-1 gene can lead to the loss of WIF-1 expression which has been observed in numerous types of cancer including NSCLC. [16,17,18,19,20] the association and clinicopathological significance between WIF-1 promoter hypermethylation and NSCLC remains unclear. We aim to systematically investigate the clinicopathological significance of WIF-1 promoter hypermethylation and NSCLC and quantify the association between WIF-1 promoter hypermethylation and NSCLC using meta-analysis www.impactjournals.com/oncotarget methods. We summarize these findings and discuss the tumor suppressor function, as well as the clinicopathological significance of WIF-1 in NSCLC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
